Zusammenfassung
Eine frühzeitig einsetzende und beschleunigt fortschreitende Atherosklerose beeinflusst signifikant die Morbidität und Mortalität von Patienten mit systemischem Lupus erythematodes (SLE). Kardiale SLE-Manifestationen sind häufig, eine pulmonale Hypertonie tritt vielfach im Verlauf der Erkrankung auf. Die Häufigkeit kardiovaskulärer Komplikationen könnte prinzipiell ein regelmäßiges Monitoring von SLE-Patienten zur frühzeitigen Diagnosestellung und Therapie rechtfertigen. Diagnostische Verfahren zum Nachweis einer Koronarinsuffizienz, die Bestimmung von Surrogatmarkern der Atherosklerose und die Echokardiographie zeigen bei SLE-Patienten häufig auffällige Befunde. Bisher gibt es jedoch keine ausreichende Evidenz für den Nutzen eines routinemäßig durchgeführten kardiovaskulären Monitorings. In Anlehnung an Empfehlungen zu anderen Erkrankungen mit kardiovaskulären Folgen schlagen wir deshalb bei asymptomatischen SLE-Patienten eine Risikofaktorevaluation und echokardiographische Kontrollen in jährlichen Abständen vor. Bei Vorliegen von mindestens 2 Risikofaktoren empfehlen wir ein Belastungs-EKG. Der Nutzen eines solchen kardiovaskulären Monitorings für SLE-Patienten ist prospektiv zu untersuchen.
Summary
Accelerated atherosclerotic cardiovascular disease is increasingly recognized as a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Cardiac manifestations of SLE are frequent and can involve almost all components of the heart. Pulmonary hypertension often develops during the course of SLE. The high incidence of cardiovascular complications may justify a screening of SLE patients in order to ensure early diagnosis and therapy. Results of diagnostic procedures that detect coronary insufficiency, surrogates of atherosclerotic burden and echocardiographic findings are often abnormal in SLE. However, evidence to support a routine screening for cardiovascular disease is currently not available. Therefore, based on the recommendations that have been proposed for other conditions associated with cardiovascular disease, we suggest assessment of risk factors and the performance of echocardiography at least annually in asymptomatic SLE patients. If two or more risk factors are present, an exercise ECG is recommended. The benefit, however, of screening SLE patients for cardiovascular disease has to be confirmed in prospective studies.
References
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore) 82:299–308
Trends in deaths from systemic lupus erythematosus–United States, 1979–1998. (2002) MMWR Morb Mortal Wkly Rep 51:371–374
Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM et al (1999) Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol 28:75–80
Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 22:1259–1264
Ward MM, Pyun E, Studenski S (1995) Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 38:1492–1499
Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60:221–225
Schattner A, Liang MH (2003) The cardiovascular burden of lupus: a complex challenge. Arch Intern Med 163:1507–1510
Wajed J, Ahmad Y, Durrington PN, Bruce IN (2004) Prevention of cardiovascular disease in systemic lupus erythematosus–proposed guidelines for risk factor management. Rheumatology (Oxford) 43:7–12
Bulkley BH, Roberts WC (1975) The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 58:243–264
Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP et al (1999) Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42:51–60
Jonsson H, Nived O, Sturfelt G (1989) Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 68:141–150
Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jr., Jansen-McWilliams L et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415
Sturfelt G, Eskilsson J, Nived O, Truedsson L, Valind S (1992) Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population. Medicine (Baltimore) 71:216–223
Haider YS, Roberts WC (1981) Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med 70:775–781
Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42:338–346
Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93:513–519
Petri M (2000) Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 9:170–175
Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH (1996) Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348:1120–1124
Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du BR et al (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44:2331–2337
Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340:115–126
Tedesco F, Fischetti F, Pausa M, Dobrina A, Sim RB, Daha MR (1999) Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol 36:261–268
Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268
Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ et al (1990) Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335:1541–1544
Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K et al (1995) Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91:23–27
Vaarala O (1996) Antiphospholipid antibodies and atherosclerosis. Lupus 5:442–447
Tuhrim S, Rand JH, Wu XX, Weinberger J, Horowitz DR, Goldman ME et al (1999) Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 30:1561–1565
Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T (1997) Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107:569–573
Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U et al (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104:1887–1893
Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M (2002) Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46:2957–2963
Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R (2001) Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 10:359–363
Leong KH, Koh ET, Feng PH, Boey ML (1994) Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21:1264–1267
Kahl LE (1992) The spectrum of pericardial tamponade in systemic lupus erythematosus. Report of ten patients. Arthritis Rheum 35:1343–1349
Mandell BF (1993) Pericardial effusion in patients with systemic lupus erythematosus: comment on the article by Kahl. Arthritis Rheum 36:1029–1030
Badui E, Garcia-Rubi D, Robles E, Jimenez J, Juan L, Deleze M et al (1985) Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 36:431–441
Doherty NE, Siegel RJ (1985) Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 110:1257–1265
Chia BL, Mah EP, Feng PH (1981) Cardiovascular abnormalities in systemic lupus erythematosus. J Clin Ultrasound 9:237–243
Moder KG, Miller TD, Tazelaar HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74:275–284
Fairfax MJ, Osborn TG, Williams GA, Tsai CC, Moore TL (1988) Endomyocardial biopsy in patients with systemic lupus erythematosus. J Rheumatol 15:593–596
Roldan CA, Shively BK, Crawford MH (1996) An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 335:1424–1430
Hojnik M, George J, Ziporen L, Shoenfeld Y (1996) Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93:1579–1587
Kao AH, Manzi S (2002) How to manage patients with cardiopulmonary disease? Best Pract Res Clin Rheumatol 16:211–227
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107:216–223
Rich S (1998) Primary pulmonary hypertension. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France. http://www.who.int/ncd/cvd/pph.html
Simonson JS, Schiller NB, Petri M, Hellmann DB (1989) Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 16:918–925
Li EK, Tam LS (1999) Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 26:1923–1929
Winslow TM, Ossipov MA, Fazio GP, Simonson JS, Redberg RF, Schiller NB (1995) Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 129:510–515
Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR (1990) Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 17:1292–1298
Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Kinoshita M, Sumiya M (1999) Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 116:174–180
Quismorio FP, Jr., Sharma O, Koss M, Boylen T, Edmiston AW, Thornton PJ et al (1984) Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13:349–359
Inglesby TV, Singer JW, Gordon DS (1973) Abnormal fibrinolysis in familial pulmonary hypertension. Am J Med 55:5–14
De Clerck LS, Michielsen PP, Ramael MR, Janssens E, Van Maercke YM, Van Marck EA et al (1991) Portal and pulmonary vessel thrombosis associated with systemic lupus erythematosus and anticardiolipin antibodies. J Rheumatol 18:1919–1921
Miyata M, Kida S, Kanno T, Suzuki K, Watanabe H, Kaise S et al (1992) Pulmonary hypertension in MCTD: report of two cases with anticardiolipin antibody. Clin Rheumatol 11:195–201
Falcao CA, Alves IC, Chahade WH, Duarte AL, Lucena-Silva N (2002) Echocardiographic abnormalities and antiphospholipid antibodies in patients with systemic lupus erythematosus. Arq Bras Cardiol 79:285–291
Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111–117
Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296–302
Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329
Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T (1997) Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 349:1365
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903
Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D et al (2003) Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108:2066–2069
Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N (2002) Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 29:282–287
Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR et al (1988) Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 78:1157–1166
Kullo IJ, Edwards WD, Schwartz RS (1998) Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med 129:1050–1060
Sicari R, Pasanisi E, Venneri L, Landi P, Cortigiani L, Picano E (2003) Stress echo results predict mortality: a large-scale multicenter prospective international study. J Am Coll Cardiol 41:589–595
Foltz WD, Al Kwifi O, Sussman MS, Stainsby JA, Wright GA (2003) Optimized spiral imaging for measurement of myocardial T2 relaxation. Magn Reson Med 49:1089–1097
Matsunari I, Taki J, Nakajima K, Tonami N, Hisada K (2003) Myocardial viability assessment using nuclear imaging. Ann Nucl Med 17:169–179
Sabharwal NK, Lahiri A (2003) Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease. Heart 89:1291–1297
Budoff MJ, Diamond GA, Raggi P, Arad Y, Guerci AD, Callister TQ et al (2002) Continuous probabilistic prediction of angiographically significant coronary artery disease using electron beam tomography. Circulation 105:1791–1796
Keelan PC, Bielak LF, Ashai K, Jamjoum LS, Denktas AE, Rumberger JA et al (2001) Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation 104:412–417
Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD (2000) Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 36:1253–1260
Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C (1991) Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 134:250–256
Grobbee DE, Bots ML (1994) Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 236:567–573
O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22
Gottenberg JE, Roux S, Assayag P, Clerc D, Mariette X (2004) Specific cardiomyopathy in lupus patients: report of three cases. Joint Bone Spine 71:66–69
Morguet AJ, Sandrock D, Stille-Siegener M, Figulla HR (1995) Indium-111-antimyosin Fab imaging to demonstrate myocardial involvement in systemic lupus erythematosus. J Nucl Med 36:1432–1435
Jolles PR, Tatum JL (1996) SLE myocarditis. Detection by Ga-67 citrate scintigraphy. Clin Nucl Med 21:284–286
Paradiso M, Gabrielli F, Masala C, Coppotelli L, Di Franco M, Paoletti V et al (2001) Evaluation of myocardial involvement in systemic lupus erythematosus by signal-averaged electrocardiography and echocardiography. Acta Cardiol 56:381–386
Been M, Thomson BJ, Smith MA, Ridgway JP, Douglas RH, Been M et al (1988) Myocardial involvement in systemic lupus erythematosus detected by magnetic resonance imaging. Eur Heart J 9:1250–1256
Marangoni S, Quadri A, Dotti A, Scalvini S, Volterrani M, Schena M et al (1988) Noninvasive assessment of pulmonary hypertension: a simultaneous echo-Doppler hemodynamic study. Cardiology 75:401–408
Sella EM, Sato EI, Barbieri A (2003) Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. Arthritis Rheum 48:3168–3175
Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF et al (2002) ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 106:1883–1892
ACC/AHA Task Force on Practice Guidelines (2002) Step six: assign classification of recommendations and and strength of evidence. In: American College of Cardiology: Manual for ACC/AHA Guideline Writing Committees. Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines. http://www.acc.org/clinical/manual/manual_index.htm
Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS (1995) Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation 92:2157–2162
O’Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM, Hachamovitch R et al (2000) American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 102:126–140
Smith SC, Jr., Greenland P, Grundy SM (2000) AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation 101:111–116
Screening for coronary heart disease: recommendation statement. (2004) Ann Intern Med 140:569–572
Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL et al (2003) ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 16:1091–1110
American Diabetes Association (2002) Standards of medical care for patients with diabetes mellitus. Diabetes Care 25:213–229
Hachulla E, Gressin V, Guillevin L, de Groote P, Cabane J, Carpentier P et al (2004) Pulmonary arterial hypertension in systemic sclerosis: definition of a screening algorithm for early detection (the ItinerAIR-Sclerodermie Study). Rev Med Interne 25:340–347
Codish S, Liel-Cohen N, Rovner M, Sukenik S, Abu-Shakra M (2004) Dobutamine stress echocardiography in women with systemic lupus erythematosus: increased occurrence of left ventricular outflow gradient. Lupus 13:101–104
Hosenpud JD, Montanaro A, Hart MV, Haines JE, Specht HD, Bennett RM et al (1984) Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 77:286–292
Lagana B, Schillaci O, Tubani L, Gentile R, Danieli R, Coviello R et al (1999) Lupus carditis: evaluation with technetium-99m MIBI myocardial SPECT and heart rate variability. Angiology 50:143–148
Bruce IN, Burns RJ, Gladman DD, Urowitz MB (2000) Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol 27:2372–2377
Sun SS, Shiau YC, Tsai SC, Lin CC, Kao A, Lee CC (2001) The role of technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography (SPECT) in the detection of cardiovascular involvement in systemic lupus erythematosus patients with non-specific chest complaints. Rheumatology (Oxford) 40:1106–1111
Sella EM, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A (2003) Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 62:1066–1070
Manger K, Kusus M, Forster C, Ropers D, Daniel WG, Kalden JR et al (2003) Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 62:846–850
Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S et al (2003) Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2407–2415
Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399–2406
Wolak T, Todosoui E, Szendro G, Bolotin A, Jonathan BS, Flusser D et al (2004) Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. J Rheumatol 31:909–914
Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH (1990) Cardiac abnormalities in systemic lupus erythematosus: a prospective M-mode, cross-sectional and Doppler echocardiographic study. Int J Cardiol 27:367–375
Crozier IG, Li E, Milne MJ, Nicholls MG (1990) Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol 65:1145–1148
Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH, Tai YT (1990) Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic lupus erythematosus. Am Heart J 120:82–87
Winslow TM, Ossipov MA, Fazio GP, Foster E, Simonson JS, Schiller NB (1993) The left ventricle in systemic lupus erythematosus: initial observations and a five-year follow-up in a university medical center population. Am Heart J 125:1117–1122
Galve E, Candell-Riera J, Pigrau C, Permanyer-Miralda G, Garcia-Del-Castillo H, Soler-Soler J (1988) Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 319:817–823
Gleason CB, Stoddard MF, Wagner SG, Longaker RA, Pierangeli S, Harris EN (1993) A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus. Am Heart J 125:1123–1129
Shen JY, Chen SL, Wu YX, Tao RQ, Gu YY, Bao CD et al (1999) Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 18:147–151
Pan TL, Thumboo J, Boey ML (2000) Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 9:338–342
Houman MH, Smiti-Khanfir M, Ben G, I, Miled M (2004) Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients. Lupus 13:204–211
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schotte, H., Becker, H., Domschke, W. et al. Kardiovaskuläres Monitoring von Patienten mit systemischem Lupus erythematodes. Z. Rheumatol. 64, 564–575 (2005). https://doi.org/10.1007/s00393-005-0668-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00393-005-0668-x
Schlüsselwörter
- Lupus, systemischer erythematodes
- Herzerkrankung, koronare
- Kardiomyopathie
- Hypertonie, pulmonale
- Monitoring